Providence Portland Medical Center

Clinical research site in Portland, Oregon · 5050 NE HOYT ST, SUITE 155, PORTLAND, OR 97213-2991 · (503) 215-6819 · Website

As of September 2026, 125 paid clinical trials are recruiting at Providence Portland Medical Center in Portland, Oregon. Active studies at this site cover conditions such as Stage IV Lung Cancer AJCC v8, Acute Myeloid Leukemia and Breast Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 1, 2026.

New trial at Providence Portland Medical Center? We'll email you when one opens.

Recruiting clinical trials at Providence Portland Medical Center (125)

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

for Breast Neoplasms

34 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: Female·Age: 18+

Code: NCT07287098·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

for Carcinoma, Transitional Cell

64 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07218380·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

for Ovarian Neoplasms

88 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07213804·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

for Colorectal Neoplasms

108 locations incl. Glendale

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

Sex: All·Age: 18+

Code: NCT05253651·Phase 3·Recruiting·Listed Feb 2022

Apply to this trial

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

for Triple-Negative Breast Cancer

82 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06393374·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

91 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06890598·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

88 locations incl. Huntsville

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

for Lymphoma, Large B-Cell, Diffuse

71 locations incl. Mobile

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06890884·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

for B-Cell Non-Hodgkins Lymphoma

33 locations incl. Anchorage

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06806033·Phase 2·Recruiting·Listed Feb 2025

Apply to this trial

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

for Breast Neoplasms

41 locations incl. Chandler

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06312176·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

for Breast Cancer

59 locations incl. Goodyear

Sponsor: Hoffmann-La Roche

Sex: All·Age: 18+

Code: NCT06790693·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

for Neoplasms

78 locations incl. Birmingham

Sponsor: Celgene

Sex: All·Age: All ages

Code: NCT03435796·Phase 2, Phase 3·Recruiting·Listed Feb 2018

Apply to this trial

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

for Leukemia, Myeloid, Acute

56 locations incl. Birmingham

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06852222·Phase 3·Recruiting·Listed Feb 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors

for Melanoma

58 locations incl. Birmingham

Sponsor: Pfizer

Sex: All·Age: 16+

Code: NCT05538130·Phase 1·Recruiting·Listed Sep 2022

Apply to this trial

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

for Metastatic Castration-resistant Prostate Cancer

46 locations incl. Birmingham

Sponsor: Celgene

Sex: Male·Age: 18+

Code: NCT06764485·Phase 3·Recruiting·Listed Jan 2025

Apply to this trial

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

for Metastatic Non-small Cell Lung Cancer With MTAP Deletion

34 locations incl. Phoenix

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07063745·Phase 2, Phase 3·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

for Melanoma

31 locations incl. Fayetteville

Sponsor: Pfizer

Sex: All·Age: 16+

Code: NCT05355701·Phase 1·Recruiting·Listed May 2022

Apply to this trial

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

for Small Cell Lung Cancer

30 locations incl. Springdale

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06203210·Phase 3·Recruiting·Listed Jan 2024

Apply to this trial

Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer (NSCLC)

19 locations incl. Fountain Valley

Sponsor: Genmab

Sex: All·Age: 18+

Code: NCT07288177·Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

for Hepatocellular Carcinoma (HCC)

11 locations incl. Duarte

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT07291076·Phase 1, Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

for Gastric Cancer

15 locations incl. New Haven

Sponsor: Daiichi Sankyo

Sex: All·Age: 18+

Code: NCT06731478·Phase 3·Recruiting·Listed Dec 2024

Apply to this trial

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

for Endometrial Cancer

17 locations incl. Birmingham

Sponsor: SystImmune Inc.

Sex: All·Age: 18+

Code: NCT06293898·Phase 1·Recruiting·Listed Mar 2024

Apply to this trial

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors

for Lung Cancer

13 locations incl. Birmingham

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06618287·Phase 1, Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

23 locations incl. Gilbert

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT03972657·Phase 1, Phase 2·Recruiting·Listed Jun 2019

Apply to this trial

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

for Small Cell Lung Cancer (SCLC)

15 locations incl. Duarte

Sponsor: Phanes Therapeutics

Sex: All·Age: 18+

Code: NCT05652686·Phase 1, Phase 2·Recruiting·Listed Dec 2022

Apply to this trial

A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

for Carcinoma, Non-Small-Cell Lung

12 locations incl. Anchorage

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT06855771·Phase 2·Recruiting·Listed Mar 2025

Apply to this trial

A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)

for Lung Neoplasm Malignant

4 locations incl. Clermont

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT07286149·Phase 1, Phase 2·Recruiting·Listed Dec 2025

Apply to this trial

A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)

for Small Cell Lung Cancer

9 locations incl. Aurora

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06780137·Phase 1, Phase 2·Recruiting·Listed Jan 2025

Apply to this trial

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

for Multiple Myeloma in Relapse

8 locations incl. Duarte

Sponsor: Kelonia Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT07075185·Phase 1·Recruiting·Listed Jul 2025

Apply to this trial

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

for Gynecologic Cancers

8 locations incl. Teaneck

Sponsor: AbbVie

Sex: Female·Age: 18+

Code: NCT07024784·Phase 2·Recruiting·Listed Jun 2025

Apply to this trial

A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors

for Advanced Solid Tumor

9 locations incl. Duarte

Sponsor: BeOne Medicines

Sex: All·Age: 18+

Code: NCT05981703·Phase 1·Recruiting·Listed Aug 2023

Apply to this trial

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

for Chronic Lymphocytic Leukemia

181 locations incl. Los Angeles

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 65+

Code: NCT07321652·Phase 3·Recruiting·Listed Jan 2026

Apply to this trial

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

for Advanced Endometrial Carcinoma

256 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT07198074·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

for Lung Non-Small Cell Carcinoma

623 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04267848·Phase 3·Recruiting·Listed Feb 2020

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1100 locations incl. Anchorage

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting·Listed May 2023

Apply to this trial

Family Communications After Genetic Testing

for Colon Adenocarcinoma

290 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+·Accepts healthy volunteers

Code: NCT07143487·Recruiting·Listed Aug 2025

Apply to this trial

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

for Astrocytoma, IDH-Mutant, Grade 3

97 locations incl. Duarte

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 12+

Code: NCT07215910·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

for Stage III Colon Cancer

915 locations incl. Fairhope

Sponsor: NRG Oncology

Sex: All·Age: 18+

Code: NCT05174169·Phase 2, Phase 3·Recruiting·Listed Dec 2021

Apply to this trial

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

for Head and Neck Squamous Cell Carcinoma

463 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT02734537·Phase 2·Recruiting·Listed Apr 2016

Apply to this trial

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

for Anatomic Stage II Breast Cancer AJCC v8

779 locations incl. Issaquah

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05812807·Phase 3·Recruiting·Listed Apr 2023

Apply to this trial

Showing the 40 most relevant of 125 recruiting trials at this site. Browse all with filters →

Get new-trial alerts for Providence Portland Medical Center

We'll email you whenever a new clinical trial starts recruiting at this research site in Portland, OR. Unsubscribe anytime.

More research sites in Portland

Oregon Health and Science University (195 trials)
Oregon Health & Science University (166 trials)
Providence Saint Vincent Medical Center (90 trials)
OHSU Knight Cancer Institute (46 trials)
Providence St. Vincent Medical Center (26 trials)
VA Portland Health Care System, Portland, OR (26 trials)
Oregon Health Sciences University (21 trials)
Oregon Health & Science University (OHSU) (19 trials)
Legacy Emanuel Children's Hospital (18 trials)
Kaiser Permanente Northwest (16 trials)

Is this your research site?

This page is built from public ClinicalTrials.gov records. If you work here, we can correct it, send you the patients who apply, and build you a free website from your real studies — verify it with your work email, or read what we do for research sites.

Explore more

Paid clinical trials in Portland, OR · Oregon clinical trials